Fu YP, Lin H, Ou YC, Wu CH, et al. Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer. BMC Cancer 2024;24:1377.
PMID: 39529011